Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the potential launch and commercialization of Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets), a centrally acting, non-opioid medication, in the US.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 20, 2024
Details:
This funding supports efforts to combat the COVID-19 pandemic through the rapid process development and manufacturing of remdesivir.
Lead Product(s): Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: COVID-19 Therapeutics Accelerator
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding November 17, 2020
Details:
Presentations highlight significant new data for key oncology drug development programmes - USP7 small molecule inhibitors and ROR1 Protein: Drug Conjugates.
Lead Product(s): ADP-c165
Therapeutic Area: Oncology Product Name: ADP-c165
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
The agreement aims at advancing the development and commercialisation of Almac's portfolio projects – ALM301. The molecule is currently in late-stage pre-clinical development, and the partner will complete this before progressing into the clinical development phase.
Lead Product(s): ALM301
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2020
Details:
Research collaboration will focus on developing new small molecule inhibitors against specific targets of Deubiquitinase to treat a variety of neurodegenerative and other diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 29, 2020